EGFR and ovarian cancer: Another study reports that an overexpression of HtrA1 in ovarian cancer cells inhibits epidermal growth factor receptor (EGFR) activation, leading to lower levels of AKT/MAPK phosphorylation and a significant rise in cell death [98].